Featuring a slide presentation and related discussion from Dr Matthew Gubens, including the following topics:
- Early-stage non-small cell lung cancer (NSCLC) with an EGFR mutation (0:00)
- Management of metastatic NSCLC with an EGFR mutation (6:34)
- Prognostic and predictive implications of plasma circulating tumor DNA for first-line therapy for metastatic NSCLC with a HER2 mutation (12:18)
- Emerging findings with immunotherapy for resectable NSCLC (13:36)
- Immunotherapy for early-stage unresectable disease (23:14)
- Emerging data with immunotherapy for metastatic NSCLC (26:00)
- Tumor treating fields with standard therapy for metastatic NSCLC after platinum failure (35:38)
- Patient-reported outcomes and emerging results with durvalumab-based therapies for extensive-stage small cell lung cancer (44:51)
CME information and select publications